These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20799244)

  • 1. Sequential generalized likelihood ratio tests for vaccine safety evaluation.
    Shih MC; Lai TL; Heyse JF; Chen J
    Stat Med; 2010 Nov; 29(26):2698-708. PubMed ID: 20799244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The costs and effectiveness of large Phase III pre-licensure vaccine clinical trials.
    Black S
    Expert Rev Vaccines; 2015; 14(12):1543-8. PubMed ID: 26414015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine trials.
    Farrington CP; Miller E
    Mol Biotechnol; 2001 Jan; 17(1):43-58. PubMed ID: 11280930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-licensure rapid immunization safety monitoring program (PRISM) data characterization.
    Baker MA; Nguyen M; Cole DV; Lee GM; Lieu TA
    Vaccine; 2013 Dec; 31 Suppl 10():K98-112. PubMed ID: 24331080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simulation study comparing exposure matching with regression adjustment in an observational safety setting with group sequential monitoring.
    Stratton KG; Cook AJ; Jackson LA; Nelson JC
    Stat Med; 2015 Mar; 34(7):1117-33. PubMed ID: 25510526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges in evaluating post-licensure vaccine safety: observations from the Centers for Disease Control and Prevention.
    Moro PL; Haber P; McNeil MM
    Expert Rev Vaccines; 2019 Oct; 18(10):1091-1101. PubMed ID: 31580725
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluating vaccine safety before and after licensure.
    Clemens J
    Bull World Health Organ; 2000; 78(2):218-9. PubMed ID: 10743289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multistage designs for vaccine safety studies.
    Dragalin V; Fedorov V
    J Biopharm Stat; 2006; 16(4):539-53. PubMed ID: 16892912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse events and vaccination-the lack of power and predictability of infrequent events in pre-licensure study.
    Jacobson RM; Adegbenro A; Pankratz VS; Poland GA
    Vaccine; 2001 Mar; 19(17-19):2428-33. PubMed ID: 11257373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updates on Vaccine Safety and Post-Licensure Surveillance for Adverse Events Following Immunization in South Korea, 2005-2017.
    Yoon D; Kim JH; Lee H; Shin JY
    Yonsei Med J; 2020 Jul; 61(7):623-630. PubMed ID: 32608206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
    Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S
    Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine safety evaluation: Practical aspects in assessing benefits and risks.
    Di Pasquale A; Bonanni P; Garçon N; Stanberry LR; El-Hodhod M; Tavares Da Silva F
    Vaccine; 2016 Dec; 34(52):6672-6680. PubMed ID: 27836435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous sequential boundaries for vaccine safety surveillance.
    Li R; Stewart B; Weintraub E; McNeil MM
    Stat Med; 2014 Aug; 33(19):3387-97. PubMed ID: 24691986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trials of rotavirus vaccines in Europe.
    Vesikari T; Giaquinto C; Huppertz HI
    Pediatr Infect Dis J; 2006 Jan; 25(1 Suppl):S42-7. PubMed ID: 16397428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety reporting in developing country vaccine clinical trials-a systematic review.
    Muehlhans S; Richard G; Ali M; Codarini G; Elemuwa C; Khamesipour A; Maurer W; Mworozi E; Kochhar S; Rundblad G; Vuitton D; Rath B
    Vaccine; 2012 May; 30(22):3255-65. PubMed ID: 22406279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccines: the pentavalent rotavirus vaccine: discovery to licensure and beyond.
    Heaton PM; Ciarlet M
    Clin Infect Dis; 2007 Dec; 45(12):1618-24. PubMed ID: 18198497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial.
    Groome MJ; Koen A; Fix A; Page N; Jose L; Madhi SA; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
    Lancet Infect Dis; 2017 Aug; 17(8):843-853. PubMed ID: 28483414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccines for preventing rotavirus diarrhoea: vaccines in use.
    Soares-Weiser K; Maclehose H; Bergman H; Ben-Aharon I; Nagpal S; Goldberg E; Pitan F; Cunliffe N
    Cochrane Database Syst Rev; 2012 Nov; 11():CD008521. PubMed ID: 23152260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development, clinical evaluation, and post-licensure impact of RotaTeq, a pentavalent rotavirus vaccine.
    Goveia MG; Ciarlet M; Owen KE; Ranucci CS
    Ann N Y Acad Sci; 2011 Mar; 1222():14-8. PubMed ID: 21434938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surveillance of adverse events following vaccination in the French armed forces, 2011-2012.
    Mayet A; Duron S; Meynard JB; Koeck JL; Deparis X; Migliani R
    Public Health; 2015 Jun; 129(6):763-8. PubMed ID: 25890634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.